Dendreon (DNDN) Ticks Higher; Analyst Sees 'Very High' Chance of EU Approving Provenge - InvestingChannel

Dendreon (DNDN) Ticks Higher; Analyst Sees ‘Very High’ Chance of EU Approving Provenge

ArticleRelated Articles (2) Stock Quotes (1) Comments (0)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

Top NewsMost Read Highlighted

Get AlertsDNDN Hot Sheet

Rating Summary:

6 Buy, 18 Hold, 8 Sell

Rating Trend: Up

Today’s Overall Ratings:

Dendreon (Nasdaq: DNDN) is ticking higher Thursday amid positive comments on approval of Provenge issued earlier.

Summer Street’s Ling Wang said checks for Provenge winning EU approval were “very high.”

One consultant from MCRI told Wang that a positive committee recommendation might happen in the first-quarter 2013, with the Committee for Advanced Therapies (CAT) possibly issuing the opinion.

Currently, Dendreon is evaluating strategic partnerships for Provenge in the EU.

Though dropping over 50 percent in the last year, shares of Dendreon are up 4.2 percent in morning trade.

For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.

Shares of Dendreon closed at $6.17 yesterday, with a 52 week range of $3.69-$17.04.

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items – JOIN NOW